Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor (nEGFR)

NCT02720185 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT02720185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02720185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor (nEGFR)
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Terminated
Start date
May 3, 2017
Completion date
February 8, 2022
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, triple negative breast neoplasms